More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

PDX Model

MSK-LX40-R

Sex: Male

Histology: Small cell lung cancer

Key Mutations: TP53 H179R, RB1 S567*, NOTCH1 P2Rfs*31,

MYCL Amplified

Molecular Characteristics: MSK-IMPACT, whole exome sequencing

Matched Normal: Yes

Treatment: LDE225 + cisplatin + etoposide, extensive cisplatin and

etoposide treatment in PDX

Site: Lung

Paired: Yes

Comments: Chemoresistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes.

MSK Office of Technology Development Contact: Alexandra Buga, MS, MBA, Licensing Associate, T: 646-888-1078, e-mail: bugaa@mskcc.org.

Stage of Development

Ready to use

Indications